Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

UNAUDITED FINANCIAL RESULTS OF

CR PHARMACEUTICAL HOLDINGS

FOR THE THREE MONTHS ENDED 31 MARCH 2021

IN RELATION TO ISSUANCES OF CORPORATE BONDS AND

MEDIUM TERM NOTES

IN THE PRC

Reference is made to the announcements of China Resources Pharmaceutical Group Limited (the "Company") dated 7 December 2018, 13 November 2019 and 30 October 2020 in relation to, among others, the proposed issuance of corporate bonds in the PRC and the announcements of the Company dated 17 August 2018, 27 August 2018 and 5 November 2018 in relation to, among others, the proposed issuance of the medium term notes in the PRC.

In accordance with the relevant rules and regulations in the PRC and in connection with

its issuances of corporate bonds and medium term notes in the PRC, China Resources Pharmaceutical Holdings Company Limited（華潤醫藥控股有限公司）("CR Pharmaceutical Holdings"), a wholly owned subsidiary of the Company, has published its audited report for

the year ended 31 December 2020 and unaudited financial statements for the three months ended 31 March 2021 on the websites of Beijing Financial Assets Exchange and the Shanghai Stock Exchange.

1

The unaudited financial statements of CR Pharmaceutical Holdings for the three months ended 31 March 2021 (the "Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings") are enclosed to this announcement for the Company's shareholders' information only. The Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings were prepared in Chinese and have been translated for publication in English and Chinese. In the event of any inconsistency between the two versions, the Chinese version shall prevail. In addition, the Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustments during the course of auditing. Such financial information is limited to CR Pharmaceutical Holdings only and does not represent or provide a complete view of the operational or financial status of the Group. Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.

By Order of the Board

China Resources Pharmaceutical Group Limited

Wang Chuncheng

Chairman

Shenzhen, 30 April 2021

As at the date of this announcement, the Board comprises Mr. Wang Chuncheng as chairman and non-executive Director, Mr. Han Yuewei, Mr. Li Xiangming and Mdm. Weng Jingwen as executive Directors, Mr. Yu Zhongliang, Mdm. Guo Wei, Mr. Hou Bo and Mr. Qing Mei Ping Cuo as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.

2

China Resources Pharmaceutical Holdings Company Limited（華潤醫藥控股有限公司）

Balance Sheet under PRC Standards

March 2021

Base currency as adjusted

Unit of monetary amounts: RMB1

As at the end

As at the beginning

As at the end

As at the beginning

Item

of the period

of the year

Item

of the period

of the year

Current assets:

Current liabilities:

Cash

241,332,732.44

463,174,272.95

Short-term borrowings

-

500,917,201.39

Trading financial assets

230,000,000.00

1,580,000,000.00

Trading financial liabilities

-

-

Derivative financial assets

-

-

Bills and trade payables

-

-

Bills receivable

-

-

Including: Bills payable

-

-

Trade receivables

-

-

Trade payables

-

-

Receivable financing

-

-

Advanced receipts

-

-

Prepayments

2,666.00

2,666.00

Contract liabilities

-

-

Other receivables

33,482,755,767.57

32,296,873,710.84

Staff remuneration payable

53,727,196.77

53,603,585.97

Including: Interest receivable

-

-

Including: Wages payable

(431,227.45)

-

Dividend receivable

3,616,748,449.32

3,616,748,449.32

Benefits payable

(90.00)

-

Inventory

-

-

Tax payable

5,236,860.66

31,818,548.04

Including: Tax amounts

Including: Raw materials

-

-

payable

5,167,427.42

31,733,119.62

Stock (finished

products)

-

-

Lease liabilities

-

-

Contract assets

-

-

Other payables

15,026,991,287.58

14,865,128,100.70

Held for sale assets

-

-

Including: Interest payable

50,700,000.01

-

Non-current assets due

within one year

-

-

Dividend payable

1,157,000,000.00

1,157,000,000.00

Other current assets

-

-

Insurance contract provision

-

-

Held-for-sale liabilities

-

-

Non-current liabilities due

within one year

3,876,296,002.55

4,093,401,993.57

Other current liabilities

-

-

Total current assets

33,954,091,166.01

34,340,050,649.79

Total current liabilities

18,962,251,347.56

19,544,869,429.67

Non-current assets:

Non-current liabilities:

Other investments in

creditor rights

-

-

Long-term borrowings

-

-

Investment in creditor rights

-

-

Bonds payable

1,184,212,875.99

1,023,203,110.00

Long-term receivables

-

-

Long-term payables

1,585,000,000.00

1,585,000,000.00

Investment in other

Including: Long-term

equity instruments

-

-

payables

1,585,000,000.00

1,585,000,000.00

Long-term equity investment

7,374,015,328.89

7,352,859,126.05

Specific payables

-

-

Long-term staff

Investment properties

-

-

remuneration payable

423,599,825.03

367,510,000.00

Other non-current financial

△ Deferred income

assets

-

-

-

-

Fixed assets

3,299,852.62

3,431,960.48

Estimated liabilities

-

-

Including: fixed asset

Deferred income tax

liquidation

120.00

120.00

liabilities

-

-

Right-of-use assets

-

-

Lease liabilities

-

-

Construction in progress

-

-

Other non-current liabilities

-

-

Including: Special

Including: Engineering supplies

-

-

reserve fund

Productive biological assets

-

-

Total non-current liabilities

3,192,812,701.02

2,975,713,110.00

Oil & gas assets

-

-

Total liabilities

22,155,064,048.58

22,520,582,539.67

3

Base currency as adjusted

Unit of monetary amounts: RMB1

As at the end

As at the beginning

As at the end

As at the beginning

Item

of the period

of the year

Item

of the period

of the year

Owners' equity

Intangible assets

495,880.56

557,649.42

(or shareholders' equity):

Paid-in capital

Including: land use rights

-

-

(share capital)

15,000,000,000.00

15,000,000,000.00

Development expenditure

-

-

State capital

Goodwill

-

-

Collective capital

Deferred expenses

-

-

Corporate capital

15,000,000,000.00

15,000,000,000.00

Including: State-owned

corporate

Deferred income tax assets

-

-

capital

15,000,000,000.00

15,000,000,000.00

Collective

corporate

Other non-current assets

31,788,191.80

31,834,091.80

capital

Including: contract assets

-

-

Individual capital

Foreign-owned capital

Other equity instrument

2,997,774,396.22

2,997,774,396.22

Capital reserve

36,455,821.78

36,455,821.78

Less: Treasury stock

-

-

Other comprehensive

income

15,740,416.58

15,740,416.58

Including: Translation

difference

on foreign-

currency

statements

-

-

Surplus reserve

585,962,101.62

585,962,101.62

Total non-current assets

7,409,599,253.87

7,388,682,827.75

Special reserve

-

-

Retained profit

572,693,635.10

572,218,201.67

Total owner's equity

attributable to the

parent company

19,208,626,371.30

19,208,150,937.87

△ Minority interests

-

-

Total owners' equity

19,208,626,371.30

19,208,150,937.87

Total liabilities and

Total assets

41,363,690,419.88

41,728,733,477.54

owners' equity

41,363,690,419.88

41,728,733,477.54

4

China Resources Pharmaceutical Holdings Company Limited（華潤醫藥控股有限公司）

Income Statement under PRC Standards

March 2021

Base currency as adjusted

Unit of monetary amounts: RMB1

Cumulative

Cumulative

amount

amount

for the same

Item

For the month

for the year

period last year

I. Operating income

-

-

-

Including: Income from principal operations

-

-

-

Income from other operations

-

-

-

II. Operating cost

-

-

-

Including: Cost of principal operations

-

-

-

Other operating costs

-

-

-

Tax and surcharges

166,852.77

179,089.81

449,197.01

Selling expenses

-

-

-

Administrative expenses

14,077,492.53

30,616,289.26

27,657,868.31

Including: Entertainment expenses

28,507.80

54,024.90

9,980.05

R&D cost

7,857,503.72

15,462,503.72

9,400,000.00

Finance cost

46,443,912.93

(24,878,280.07)

27,109,186.61

Including: Interest expenses

17,467,477.88

52,947,496.61

60,967,309.59

Interest income

55,518,165.32

105,831,985.74

132,141,925.67

Exchange loss, net

(net gain indicated by "-")

84,490,903.40

27,993,135.60

97,724,536.69

Other gains

240,506.94

240,506.94

-

Investment gain (Loss indicated by "-")

14,733,522.08

21,614,529.21

8,206,369.98

Including: Gain from investment in associates

and joint ventures

14,733,522.08

21,156,202.84

-

Derecognition of gain from financial assets at

amortised cost

-

-

-

Gain from net exposure hedging

(Loss indicated by "-")

-

-

-

Add: Gain from change in fair value

(Loss indicated by "-")

-

-

-

Asset impairment loss

-

-

-

Credit impairment loss

-

-

-

Gain from asset disposal

-

-

-

5

Base currency as adjusted

Unit of monetary amounts: RMB1

Cumulative

Cumulative

amount

amount

for the same

Item

For the month

for the year

period last year

III.Operating profit (Loss indicated by "-")

(53,571,732.93)

475,433.43

(56,409,881.95)

Add: Non-operating income

-

-

-

Including: Gain from non-monetary asset swap

-

-

-

Government grants

-

-

-

Less: Non-operating expenses

-

-

1,246.48

Including: Loss on non-monetary asset swap

-

-

-

IV. Total profit (Total loss indicated by "-")

(53,571,732.93)

475,433.43

(56,411,128.43)

Less: Income tax expenses

-

-

-

V. Net profit (Net loss indicated by "-")

(53,571,732.93)

475,433.43

(56,411,128.43)

Including: Net profit of the absorbed party

prior to combination in a business

combination of parties under

common control

Net profit attributable to owners of the parent company

(53,571,732.93)

475,433.43

(56,411,128.43)

* Minority interests

-

-

-

Profit attributable to holders of perpetual capital

instruments

-

-

-

6

China Resources Pharmaceutical Holdings Company Limited（華潤醫藥控股有限公司）

Cash Flow Statement under PRC Standards

March 2021

Base currency as adjusted

Unit of monetary amounts: RMB1

Cumulative

Cumulative

amount

amount

for the same

Item

For the month

for the year

period last year

I.

Cash flows from operating activities

Cash received from sale of goods or

rendering of labour services

-

-

-

Refunds of taxes

254,937.36

254,937.36

-

Other cash received in relation to

operating activities

(200.00)

200,000,000.00

250,541,969.24

Sub-total of cash inflows from

operating activities

254,737.36

200,254,937.36

250,541,969.24

Cash paid for goods and labour services

48,364.32

100,575.94

25,893.38

Cash paid to and on behalf of employees

6,857,013.12

21,526,015.23

21,727,439.63

Payment of various taxes

9.70

28,474,314.54

4,528,754.76

Other cash paid in relation to operating activities

41,153,115.89

279,690,012.12

213,942,711.05

Sub-total of cash outflows from operating activities

48,058,503.03

329,790,917.83

240,224,798.82

Net cash flows from operating activities

(47,803,765.67)

(129,535,980.47)

10,317,170.42

II. Cash flows from investing activities

Cash received from sale of investments

1,998,000,000.00

8,848,000,000.00

12,578,758,246.58

Cash received from return on investment

32,264,683.47

32,723,009.84

42,608,353.70

Cash received from the disposal of fixed assets,

intangible assets and other long-term assets, net

-

-

-

Cash received for the disposal of subsidiaries

and other business units, net

-

-

-

Other cash received in relation to investing activities

1,372,940.80

1,927,596.10

1,173,682.04

Sub-total of cash inflows from investing activities

2,031,637,624.27

8,882,650,605.94

12,622,540,282.32

Cash paid for acquisition of fixed assets,

intangible assets and other long-term assets, net

10,497.00

26,226.08

66,531.00

Cash paid for acquisition of investments

2,000,000,000.00

8,550,000,000.00

13,515,000,000.00

Cash paid for the acquisition of subsidiaries

and other business units, net

-

-

-

Other cash paid in relation to investing activities

-

-

-

Sub-total of cash outflows from investing activities

2,000,010,497.00

8,550,026,226.08

13,515,066,531.00

Net cash flows from investing activities

31,627,127.27

332,624,379.86

(892,526,248.68)

7

Base currency as adjusted

Unit of monetary amounts: RMB1

Cumulative

Cumulative

amount

amount

for the same

Item

For the month

for the year

period last year

III.Cash flows from financing activities

Cash received from investments

-

-

-

Including: Capital injection into subsidiaries

by minority shareholders

Cash received from borrowings

-

-

-

Cash received from bond issuance

-

-

2,000,000,000.00

Other cash received in relation to financing activities

346,888,842.73

894,021,664.91

605,758,328.79

Sub-total of cash inflows from financing activities

346,888,842.73

894,021,664.91

2,605,758,328.79

Cash repayment of borrowings

-

500,000,000.00

750,000,000.00

Cash payments for distribution of dividends or

for interest expenses

-

3,085,131.94

2,751,604.17

Including: Distribution of dividends and profits by

subsidiaries to minority shareholders

-

-

-

Other cash paid in relation to financing activities

291,304,510.54

815,866,476.24

527,040,457.85

Sub-total of cash outflows from financing activities

291,304,510.54

1,318,951,608.18

1,279,792,062.02

Net cash flows from financing activities

55,584,332.19

(424,929,943.27)

1,325,966,266.77

IV. Effect of changes in foreign exchange rate on cash and

cash equivalents

10.16

3.37

17.02

V. Net increase in cash and cash equivalents

39,407,703.95

(221,841,540.51)

443,757,205.53

Add: cash and cash equivalents at the beginning of the

period

201,924,232.51

463,173,476.97

229,087,150.33

VI. Net balance of cash and cash equivalents at the end of

the period

241,331,936.46

241,331,936.46

672,844,355.86

8

China Resources Pharmaceutical Holdings Company Limited（華潤醫藥控股有限公司）

(Consolidated)

Balance Sheet under PRC Standards

March 2021

Base currency

Unit of monetary amounts: RMB1

As at the end of

As at the beginning of

As at the end

As at the beginning

Item

the period

the year

Item

of the period

of the year

Current assets:

Current liabilities:

Cash

16,795,109,852.35

14,529,867,477.45

Short-term borrowings

33,963,147,521.39

25,604,457,746.44

Trading financial assets

6,064,294,297.62

5,812,710,752.01

Trading financial liabilities

-

-

Derivative financial assets

-

-

Bills and trade payables

42,566,130,414.20

38,738,962,436.16

Bills receivable

3,306,968,833.53

591,971,746.66

Including: Bills payable

13,684,669,248.27

12,185,068,936.68

Trade receivables

56,134,890,511.43

49,122,678,629.31

Trade payables

28,881,461,165.93

26,553,893,499.48

Receivable financing

20,623,959,449.08

23,312,821,453.57

Advanced receipts

4,584,156.93

1,659,583.68

Prepayments

4,643,640,934.37

3,169,326,807.81

Contract liabilities

3,388,955,818.85

2,083,719,051.61

Other receivables

6,144,291,762.17

4,538,996,611.67

Staff remuneration payable

1,415,214,034.75

1,851,799,474.61

Including: Interest receivable

26,736,197.05

3,420,401.80

Including: Wages payable

363,219,057.71

525,386,476.15

Dividend receivable

(0.00)

(0.00)

Benefits payable

11,263,697.10

12,500,541.79

Inventory

22,649,544,234.00

20,672,463,121.16

Tax payable

794,446,769.22

1,212,385,373.56

Including: Tax amounts

Including: Raw materials

2,127,088,609.95

2,207,087,388.51

payable

789,948,665.70

1,009,608,342.81

Stock

(finished products)

18,492,127,137.99

16,715,710,429.44

Lease liabilities

24,526,885.90

-

Contract assets

16,000,720.17

0.00

Other payables

31,993,386,397.57

33,085,921,813.69

Held for sale assets

-

-

Including: Interest payable

158,333,225.13

94,952,043.59

Non-current assets due

within one year

418,258,769.47

533,378,054.31

Dividend payable

4,349,121,918.39

4,381,106,484.22

Other current assets

486,493,684.56

650,296,082.25

Insurance contract provision

-

-

Held-for-sale liabilities

-

-

Non-current liabilities due

within one year

4,340,561,697.05

4,631,275,351.77

Other current liabilities

161,848,772.64

152,068,605.71

Total current assets

137,283,453,048.75

122,934,510,736.20

Total current liabilities

118,652,802,468.51

107,362,249,437.24

Non-current assets:

Non-current liabilities:

Other investments in

creditor rights

(0.25)

(0.25)

Long-term borrowings

849,010,222.00

662,437,631.72

Investment in creditor rights

730,000,000.00

972,340,592.24

Bonds payable

1,184,212,875.99

1,023,203,110.00

Long-term receivables

164,198,487.87

786,206,417.09

Long-term payables

1,749,704,246.71

1,762,889,363.58

Investment in other equity

Including: Long-term

instruments

2,265,589.19

2,265,589.19

payables

1,594,230,694.54

1,592,798,652.27

Long-term equity investment

4,317,771,661.15

4,618,874,723.32

Specific payables

155,473,552.17

170,090,711.31

Long-term staff

Investment properties

349,658,371.95

356,824,360.26

remuneration payable

909,051,613.96

854,334,488.08

Other non-current financial assets

504,552,035.13

504,689,442.79

△ Deferred income

563,324,211.70

548,278,237.13

Fixed assets

13,221,474,344.76

13,064,805,388.40

Estimated liabilities

3,465,031.95

3,465,031.95

Including: fixed asset

Deferred income tax

liquidation

3,537,213.65

3,473,158.22

liabilities

1,307,217,858.35

1,297,867,201.34

Right-of-use assets

1,327,993,514.75

-

Lease liabilities

1,380,031,072.39

-

Construction in progress

923,673,748.17

906,676,008.04

Other non-current liabilities

17,693,950.92

14,628,843.69

Including: Engineering

Including: Special

supplies

-

-

reserve fund

Productive biological assets

18,189,442.66

20,968,975.15

Total non-current liabilities

7,963,711,083.97

6,167,103,907.49

Oil & gas assets

-

-

Total liabilities

126,616,513,552.48

113,529,353,344.74

9

Base currency

Unit of monetary amounts: RMB1

As at the end of

As at the beginning of

As at the end

As at the beginning

Item

the period

the year

Item

of the period

of the year

Owners' equity

Intangible assets

8,048,569,072.39

7,988,644,032.90

(or shareholders' equity):

Including: land use rights

3,044,861,651.65

3,018,147,953.63

Paid-in capital (share capital)

15,000,000,000.00

15,000,000,000.00

Development expenditure

1,043,708,270.40

989,953,461.97

State capital

Goodwill

17,783,626,833.54

17,735,146,658.69

Collective capital

Deferred expenses

296,048,618.63

301,429,811.12

Corporate capital

15,000,000,000.00

15,000,000,000.00

Including: State-owned

Deferred income tax assets

801,764,341.61

785,688,746.56

corporate capital

15,000,000,000.00

15,000,000,000.00

Collective

corporate

Other non-current assets

688,994,499.38

460,295,188.20

capital

Including: contract assets

21,625,483.89

138,030,840.84

Individual capital

Foreign-owned capital

Other equity instrument

2,997,774,396.22

2,997,774,396.22

Capital reserve

337,324,513.43

337,255,067.23

Less: Treasury stock

0.00

(0.00)

Other comprehensive income

2,590,368.29

2,565,574.01

Including: Translation

difference on foreign-

currency statements

(3,876,217.73)

(3,901,012.01)

Surplus reserve

360,810,887.95

360,810,887.94

Total non-current assets

50,222,488,831.33

49,494,809,395.66

Special reserve

785,077.17

606,261.96

Retained profit

10,430,357,890.76

9,769,143,857.07

Total owner's equity

attributable to the

parent company

29,129,643,133.81

28,468,156,044.42

△ Minority interests

31,759,785,193.97

30,431,810,742.69

Total owners' equity

60,889,428,327.78

58,899,966,787.12

Total liabilities and owners'

Total assets

187,505,941,880.08

172,429,320,131.86

equity

187,505,941,880.26

172,429,320,131.85

10

China Resources Pharmaceutical Holdings Company Limited（華潤醫藥控股有限公司）

(Consolidated)

Income Statement under PRC Standards

March 2021

Base currency

Unit of monetary amounts: RMB1

Cumulative

Cumulative

amount for

amount

the same period

Item

For the month

for the year

last year

I. Operating income

15,944,734,471.68

47,105,616,838.06

37,921,794,647.76

Including: Income from principal operations

15,779,933,481.85

46,719,843,036.25

37,652,381,861.03

Income from other operations

164,800,989.82

385,773,801.81

269,412,786.73

II. Operating cost

13,443,614,934.91

39,589,830,044.77

31,795,120,625.77

Including: Cost of principal operations

13,379,994,888.18

39,440,575,699.56

31,662,528,833.66

Other operating costs

63,620,046.73

149,254,345.21

132,591,792.11

Tax and surcharges

74,593,320.31

199,727,800.13

156,645,225.61

Selling expenses

1,313,810,854.97

3,603,798,664.82

3,057,490,325.42

Administrative expenses

361,435,489.65

1,037,075,230.88

853,562,571.16

Including: Entertainment expenses

6,650,436.73

16,046,372.22

8,882,487.52

R&D cost

92,021,018.85

241,368,302.34

176,262,915.97

Finance cost

281,282,466.73

521,140,377.04

583,153,508.12

Including: Interest expenses

222,965,661.64

516,298,289.50

481,104,391.11

Interest income

40,179,041.77

53,619,959.05

78,899,869.27

Exchange loss, net

(net gain indicated by "-")

85,302,862.54

27,848,043.11

93,792,924.16

Other gains

35,362,917.49

62,722,851.81

111,466,975.70

Investment gain (Loss indicated by "-")

19,001,036.12

67,209,451.62

56,989,264.50

Including: Gain from investment in associates

and joint ventures

13,211,274.59

39,130,170.76

27,454,303.94

Derecognition of gain from financial assets

at amortised cost

-

-

-

Gain from net exposure hedging

(Loss indicated by "-")

-

-

-

Add: Gain from change in fair value

(Loss indicated by "-")

15,736,515.46

30,613,264.60

12,904,537.39

Asset impairment loss

1,140,549.53

36,603,060.16

(861,543.87)

Credit impairment loss

66,082,246.43

168,706,656.85

67,470,715.38

Gain from asset disposal

6,046,314.72

9,065,716.34

417,173.23

11

Base currency

Unit of monetary amounts: RMB1

Cumulative

Cumulative

amount for

amount

the same period

Item

For the month

for the year

last year

III.Operating profit (Loss indicated by "-")

386,900,374.09

1,876,977,985.45

1,414,728,255.03

Add: Non-operating income

5,897,177.11

20,582,631.42

28,004,845.92

Including: Gain from non-monetary asset swap

-

-

-

Government grants

500,599.38

815,679.07

1,892,135.93

Less: Non-operating expenses

3,392,505.28

6,925,291.11

18,591,954.83

Including: Loss on non-monetary asset swap

-

-

-

IV. Total profit (Total loss indicated by "-")

389,405,045.92

1,890,635,325.76

1,424,141,146.12

Less: Income tax expenses

47,182,998.83

372,073,136.58

338,623,242.31

V. Net profit (Net loss indicated by "-")

342,222,047.09

1,518,562,189.18

1,085,517,903.80

Including: Net profit of the absorbed party prior to

combination in a business combination of

parties under common control

Net profit attributable to owners of the parent company

104,362,569.82

687,308,025.52

508,918,459.97

*Minority interests

237,859,477.27

831,254,163.66

576,599,443.84

Profit attributable to holders of perpetual

capital instruments

-

-

-

12

China Resources Pharmaceutical Holdings Company Limited（華潤醫藥控股有限公司）

(Consolidated)

Cash Flow Statement under PRC Standards

March 2021

Base currency

Unit of monetary amounts: RMB1

Cumulative

Cumulative

amount for

amount

the same period

Item

For the month

for the year

last year

I.

Cash flows from operating activities

Cash received from sale of goods or

rendering of labour services

18,939,391,162.82

48,177,047,119.47

41,490,582,117.17

Refunds of taxes

89,951,697.43

117,227,075.33

6,391,303.52

Other cash received in relation to operating activities

1,956,455,915.84

4,881,644,085.58

5,514,581,491.19

Sub-total of cash inflows from operating activities

20,985,798,776.09

53,175,918,280.38

47,011,554,911.89

Cash paid for goods and labour services

16,271,109,882.99

44,232,077,420.79

39,389,806,901.04

Cash paid to and on behalf of employees

680,229,729.34

2,674,303,527.30

2,420,547,597.12

Payment of various taxes

248,615,629.20

1,970,815,516.66

1,545,942,633.51

Other cash paid in relation to operating activities

3,935,318,900.21

8,863,144,622.64

7,733,504,016.52

Sub-total of cash outflows

from operating activities

21,135,274,141.74

57,740,341,087.39

51,089,801,148.19

Net cash flows from operating activities

(149,475,365.65)

(4,564,422,807.01)

(4,078,246,236.30)

II. Cash flows from investing activities

Cash received from sale of investments

1,929,155,892.69

6,152,530,540.42

7,657,711,088.80

Cash received from return on investment

36,056,150.26

65,329,847.23

85,258,718.26

Cash received from the disposal of fixed assets,

intangible assets and other long-term assets, net

11,597,511.67

13,984,214.73

5,736,920.82

Cash received for the disposal of subsidiaries and other

business units, net

-

-

648,050,589.71

Other cash received in relation to investing activities

5,438,656.17

49,577,716.99

95,457,474.66

Sub-total of cash inflows from investing activities

1,982,248,210.79

6,281,422,319.37

8,492,214,792.25

Cash paid for acquisition of fixed assets, intangible assets

and other long-term assets, net

105,307,609.90

402,038,387.82

298,193,009.79

Cash paid for acquisition of investments

1,751,461,227.00

6,790,422,136.71

9,998,000,000.00

Cash paid for the acquisition of subsidiaries and other

business units, net

32,637,985.66

255,438,911.39

948,550,052.00

Other cash paid in relation to investing activities

20,000.00

2,116,422.41

32,931,838.88

Sub-total of cash outflows from investing activities

1,889,426,822.56

7,450,015,858.33

11,277,674,900.67

Net cash flows from investing activities

92,821,388.23

(1,168,593,538.96)

(2,785,460,108.42)

13

Base currency

Unit of monetary amounts: RMB1

Cumulative

Cumulative

amount for

amount

the same period

Item

For the month

for the year

last year

III.Cash flows from financing activities

Cash received from investments

-

13,475,000.00

-

Including: Capital injection into subsidiaries by

minority shareholders

Cash received from borrowings

8,388,658,034.58

22,357,155,458.11

22,585,704,896.60

Cash received from bond issuance

-

-

2,000,000,000.00

Other cash received in relation to financing activities

4,241,405,317.11

4,796,127,940.72

3,477,989,461.39

Sub-total of cash inflows from financing activities

12,630,063,351.69

27,166,758,398.83

26,063,694,357.99

Cash repayment of borrowings

5,577,067,390.67

15,090,286,022.80

13,048,021,430.90

Cash payments for distribution of dividends or for

interest expenses

194,269,855.27

390,021,544.23

654,609,644.67

Including: Distribution of dividends and profits by

subsidiaries to minority shareholders

-

-

-

Other cash paid in relation to financing activities

3,160,143,007.75

3,692,653,879.65

4,546,337,058.15

Sub-total of cash outflows from financing activities

8,931,480,253.69

19,172,961,446.68

18,248,968,133.72

Net cash flows from financing activities

3,698,583,098.00

7,993,796,952.15

7,814,726,224.27

IV. Effect of changes in foreign exchange rate on cash and

cash equivalents

(870,709.35)

2,222,988.55

1,625,041.62

V. Net increase in cash and cash equivalents

3,641,058,411.24

2,263,003,594.72

952,644,921.17

Add: cash and cash equivalents at the beginning

of the period

7,930,301,039.69

9,308,355,856.20

10,994,852,531.35

VI. Net balance of cash and cash equivalents at the end of

the period

11,571,359,450.93

11,571,359,450.93

11,947,497,452.52

14

Attachments

  • Original document
  • Permalink

Disclaimer

China Resources Pharmaceutical Group Ltd. published this content on 30 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2021 11:19:00 UTC.